BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20074801)

  • 1. The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia.
    Tarnani M; Laurenti L; Longo PG; Piccirillo N; Gobessi S; Mannocci A; Marietti S; Sica S; Leone G; Efremov DG
    Leuk Res; 2010 Sep; 34(9):1189-94. PubMed ID: 20074801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
    Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
    Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosome study on chronic lymphocytic leukemia using CpG-oligodeoxynucleotide as immunostimulant agent].
    Wu Y; Xue Y; Chen S; Yao L; Jiang H; Zhang J; Shen J; Pan J; Wang Y; Bai S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):86-91. PubMed ID: 20140876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.
    Vlad A; Deglesne PA; Letestu R; Saint-Georges S; Chevallier N; Baran-Marszak F; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
    Cancer Res; 2009 Aug; 69(16):6387-95. PubMed ID: 19654311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
    Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
    J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia.
    Ghalamfarsa G; Jadidi-Niaragh F; Hojjat-Farsangi M; Asgarian-Omran H; Yousefi M; Tahmasebi F; Khoshnoodi J; Razavi SM; Saboor-Yaraghi AA; Rabbani H; Jeddi-Tehrani M; Shokri F
    Cytokine; 2013 Jun; 62(3):439-45. PubMed ID: 23579027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance.
    Rigolin GM; Maffei R; Rizzotto L; Ciccone M; Sofritti O; Daghia G; Cibien F; Cavazzini F; Marasca R; Cuneo A
    Cancer; 2010 Apr; 116(8):1926-37. PubMed ID: 20166207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia.
    Liso V; Capalbo S; Lapietra A; Pavone V; Guarini A; Specchia G
    Haematologica; 1999 Mar; 84(3):212-7. PubMed ID: 10189384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans-retinoic Acid differentially regulates proliferation of normal and leukemic B cells from different subsets of chronic lymphocytic leukemia.
    Ghalamfarsa G; Jadidi-Niaragh F; Amiri MM; Razavi SM; Saboor-Yaraghi AA; Shokri F
    Nutr Cancer; 2015; 67(2):285-91. PubMed ID: 25611428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia.
    Jaksic O; Vrhovac R; Kusec R; Kardum MM; Pandzic-Jaksic V; Kardum-Skelin I; Planinc-Peraica A; Morabito F; Brugiatelli M; Jaksic B
    Haematologica; 2001 Aug; 86(8):827-36. PubMed ID: 11522539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
    Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
    Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.